LBRX

NASDAQ 已收盘

LB Pharmaceuticals

40.04 USD
▼-0.02-0.05%
盘后 41.00 +2.40%
2026-11-19
市值
$1.26B
市盈率
—
EPS
-4.82
股息率
—
52 周区间
15.19 – 50.16
成交量
405.43K
Beta
—
目标价
58.00
52W 低 15.1952W 高 50.16
价格走势

公司简介

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New ...